Porcilis Ery
Revised: March 2015
AN: 01446/2014
Summary of Product Characteristics
1. Name of the veterinary medicinal product
Porcilis Ery
2. Qualitative and quantitative composition of product
Per dose:
Active substance:
Erysipelothrix rhusiopathiae strain M2 (serotype 2) ≥ 1 ppd*
* ppd = pig protective dose
Excipients:
dl α-tocopherol acetate (adjuvant) 150 mg
Formaldehyde (preservative) 0.05%
3. PHARMACEUTICAL FORM
Suspension for injection.
4. CLINICAL PARTICULARS
4.1 Target species
Pigs.
4.2 Indications for use
For the active immunisation of sows, gilts, boars and growing pigs as an aid in the control of swine erysipelas.
4.3 Contraindications
Do not vaccinate unhealthy animals.
4.4 Special warnings for each target species
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
4.5 Special precautions for use
Special precaution for use in animals
None.
Special precautions to be taken by the person administering the product to animals
None.
4.6 Adverse reactions (frequency and seriousness)
Vaccination reactions normally consist of a slight (0.5C), transient (normal within 24 hours) rise in body temperature. A mild local swelling (less than 5 cm in diameter, normal within 3 days) and some reluctance to move may be seen in a very small proportion (<5%) of vaccinated animals.
4.7 Use during pregnancy, lactation or lay
Stress should be avoided when vaccinating animals, particularly during later stages of pregnancy.
4.8 Interaction with other medicaments and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
4.9 Amounts to be administered and administration route
The dose is 2 ml per pig, given by deep intramuscular injection behind the ear.
Ensure that vaccination equipment is clean and sterile before use.
Allow vaccine to reach room temperature (15 - 25 C) before use.
Shake well before and during use.
Vaccination program
Young growing pigs
Pigs should be at least 6 weeks of age. A course of two vaccinations given 4 weeks apart, is recommended.
Breeding stock
Primary vaccination:
For the induction of protection against erysipelas, an initial course of two vaccinations, given 4 weeks apart, is recommended. Where protection against parvovirus is also required, this can be achieved with Porcilis Ery given either 4 weeks before, or 4 weeks after,administration of the Porcilis Ery+Parvo. Boars and gilts should be vaccinated against E. rhusiopathiaeat least 2 weeks before mating.
Booster vaccination:
Sows and boars should be revaccinated against erysipelas at six monthly intervals. For sows this may be during each lactation period, at weaning or during pregnancy (avoiding the last two weeks).
4.10 Overdose (symptoms, emergency procedures, antidotes)(if necessary)
No additional symptoms at double dose.
4.11 Withdrawal periods
Zero days.
5. IMMUNOLOGICAL PROPERTIES
The active substance is inactivated antigen of Erysipelothrix rhusiopathiae which induces active immunity in vaccinated animals. The antigen is incorporated in an aqueous tocopherol based adjuvant in order to give a prolonged stimulation of immunity.
ATC Vet code: QI09AB03
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Formaldehyde, dl α-tocopherol acetate, polysorbat, simethicone, buffer
6.2 Incompatibilities
Do not mix with any other veterinary medicinal product.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
In use shelf life: 10 hours.
6.4 Special precautions for storage
Store at 2 C - 8 C. Protect from light. Do not freeze.
6.5 Nature and composition of immediate packaging
Cardbox box with glass (Type I Ph.Eur.) or PET vial containing 10, 25, 50 or 125 doses (20, 50, 100 or 250 ml respectively), closed with a rubber stopper and sealed with a colour coded aluminium cap.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal of unused veterinary medicinal product or waste material derived from the use of such products
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
7. maRKETING AUTHORISATION holder
Intervet UK Ltd
Walton Manor
Walton
Milton Keynes
Buckinghamshire
MK7 7AJ
8. Marketing Authorisation Number
Vm 01708/4355
9. DATE OF FIRST AUTHORISATION
Date: 07 July 1997
10. Date of revision of the text
Date:March 2015
Approved: 30 March 2015
Page 4 of 4